多药耐药相关蛋白基因在非小细胞肺癌表达的临床意义

目的 探索多药耐药相关蛋白（ＭＲＰ）在非小细胞肺癌（ＮＳＣＬＣ）的表达，以及与病理类型、病期及预后的关系。方法 以原位杂交法检测冰冻ＮＳＣＬＣ组织。结果 全组５８例ＮＳＣＬＣ、ＭＲＰＭＲＮＡ总表达率为７４．１％，鳞癌为７２．０％，腺癌为７３．３％。ＭＲＰ的表达与病理类型、ＴＮＭ发期及分化程度无关。４７例接受化疗的ＮＳＣＬＣ中，３５例ＭＲＰ表达者生存率明显低于ＭＲＰ表达者，中位生存期分别为８．７个月

Clinical significance of multidrug resistance associated protein(MRP) gene expression in non small cell lung cancer

OBJECTIVE: To investigate expression of multidrug resistance-associated protein (MRP) in non-small cell lung cancer and its relation to histological type, TNM staging and prognosis. METHODS: In situ hybridization was used to examine mRNA expression of MRP. RESULTS: The overall positive rate of MRP expression was 74.1%, with 73.3% and 72.0% in adenocarcinoma and squamous-cell carcinoma, respectively. The expression of MRP was not related to histological subtypes, TNM staging and cell differentiation. In 47 patients who received chemotherapy, 35 patients with positive MRP expression(+(-)++) showed worse prognosis than in those with negative expression (P < 0.05). The median survival time was 8.7 months and 21 months in patients with positive and negative MRP expession, respectively. In patients with squamous-cell carcinoma, the survival rate was significantly lower in patients (n = 12) with positive MRP expression than in those (n = 7) with negative MRP expression (P < 0.05). Their median survival time was 6 months and 19.5 months, respectively (P < 0.05). CONCLUSION: The expression of MRP gene is negatively correlated with survival of patients with squamous-cell carcinoma, but not adenocarcinoma, who received chemotherapy.